Brief: Innate Pharma 2023 Net Loss EUR 7.6 Mln, Vs EUR 58.1 Mln YoY

Innate Pharma SA

21/03/2024 06:09

March 21 (Reuters) - Innate Pharma SA  IPH.PA :
    * POSITIVE FINAL RESULTS OF LACUTAMAB TELLOMAK PHASE 2 TRIAL
IN
SÉZARY SYNDROME PRESENTED AT ASH ANNUAL MEETING 2023
    * CASH POSITION OF €102.3 MILLION AS OF DECEMBER 31, 2023
EXCLUDING THE €15M FROM SANOFI, ANTICIPATED CASH RUNWAY TO END
OF 2025
    * FINAL DATA IN MYCOSIS FUNGOIDES TO BE SHARED AT AN
UPCOMING
MEDICAL CONGRESS
    * OPERATING EXPENSES FROM CONTINUING OPERATIONS AND BEFORE
IMPAIRMENT AMOUNTED TO EUR 74.3M IN 2023 (2022: EUR 74.1M,
+0.3%)
    * 2023 REVENUE AND OTHER INCOME FROM CONTINUING OPERATIONS
€61.6M
IN 2023 (2022: €57.7M, +6.9%)
    * A NET FINANCIAL INCOME OF EUR 5.1M IN 2023 (2022: EUR 0.5M
LOSS)
    * 2023 NET LOSS OF €7.6M IN 2023 (2022: NET LOSS OF €58.1M)

Source text: shorturl.at/efgJ9
Further company coverage:  IPH.PA 

 (Gdansk Newsroom)
 ((gdansknewsroom@thomsonreuters.com; + 48 58 7785110;))